W. Dunlop

The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

Ashok Kumar Jha, Alex Upton, W. Dunlop et al. · Advances in Therapy · 2015 · 146 citations · Full text

Cost-Effectiveness of Take-Home Naloxone for the Prevention of Overdose Fatalities among Heroin Users in the United Kingdom

Sue Langham, Antony Wright, James Kenworthy et al. · Value in Health · 2018 · 69 citations · Full text

Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis

W. Dunlop, Reiner Uhl, Iftekhar Khan et al. · Journal of Medical Economics · 2012 · 46 citations

Estimating the health care burden of prescription opioid abuse in five European countries

Amie Shei, Matthew Hirst, Noam Y. Kirson et al. · ClinicoEconomics and Outcomes Research · 2015 · 42 citations · Full text

Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience

W. Dunlop, Alexandra Staufer, Pierre Lévy et al. · Health Policy · 2018 · 34 citations · Full text